Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial

被引：0
|
作者：
Renata Ferrarotto
Luana G. Sousa
Yun Qing
Diana Kaya
Bettzy Stephen
Dipti Jain
Diana Bell
Shubham Pant
Apostolia M. Tsimberidou
Filip Janku
George Blumenschein
Bonnie S. Glisson
Jordi Rodon Ahnert
Sarina A. Piha-Paul
J. Jack Lee
Michael K. Wong
Charles Lu
Funda Meric-Bernstam
Aung Naing
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Thoracic/Head and Neck Medical Oncology
[2] The University of Texas MD Anderson Cancer Center,Department of Biostatistics
[3] The University of Texas MD Anderson Cancer Center,Department of Radiology
[4] The University of Texas MD Anderson Cancer Center,Department of Investigational Cancer Therapeutics
[5] The University of Texas MD Anderson Cancer Center,Department of Pathology
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Pembrolizumab; Checkpoint inhibitor; Rare cancers; Cutaneous squamous cell carcinoma; Skin cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4581 / 4591
页数：10
相关论文
共 50 条
  • [21] Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma
    Giri, Anshu
    Bauman, Jessica R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (10) : 1029 - 1038
  • [22] Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT).
    Adra, Nabil
    Althouse, Sandra K.
    Ammakkanavar, Natraj Reddy
    Radovich, Milan
    Albany, Costantine
    Vaughn, David J.
    Einhorn, Lawrence H.
    Hanna, Nasser H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma
    Degache, E.
    Crochet, J.
    Simon, N.
    Tardieu, M.
    Trabelsi, S.
    Moncourier, M.
    Templier, I.
    Foroni, L.
    Lemoigne, A.
    Pinel, N.
    Gil, H.
    Bouillet, L.
    Leccia, M. T.
    Charles, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (07) : E257 - E258
  • [24] Randomized phase II selection trial of FLASH and conventional radiotherapy for patients with localized cutaneous squamous cell carcinoma or basal cell carcinoma: A study protocol
    Kinj, Remy
    Gaide, Olivier
    Jeanneret-Sozzi, Wendy
    Dafni, Urania
    Viguet-Carrin, Stephanie
    Sagittario, Enea
    Kypriotou, Magdalini
    Chenal, Julie
    Duclos, Frederic
    Hebeisen, Marine
    Falco, Teresa
    Geyer, Reiner
    Jorge, Patrik Gonsalves
    Moeckli, Raphael
    Bourhis, Jean
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2024, 45
  • [25] A phase II trial of ZD 1839 (Gefitinib) for advanced cutaneous squamous cell carcinoma of head and neck
    Weber, R. S.
    Glisson, B. S.
    Taylor, S. A.
    Hanna, E. Y.
    El-Naggar, A. K.
    Chambers, M. S.
    ORAL ONCOLOGY, 2009, : 190 - 190
  • [26] KEYNOTE-629: Phase II study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma
    Grob, Jean-Jacques
    Gonzalez Mendoza, Rene
    Basset-Seguin, Nicole
    Schachter, Jacob
    Vornicova, Olga
    Bauman, Jessica
    Grange, Florent
    Meyer, Nicolas
    Piulats, Josep
    Zhang, Pingye
    Gumuscu, Burak
    Swaby, Ramona
    Hughes, Brett G. M.
    CANCER RESEARCH, 2019, 79 (13)
  • [27] Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
    Coutzac, C.
    Bigot, F.
    Vansteene, D.
    Dos Santos, M.
    Ghiringhelli, F.
    You, B.
    Lambert, A.
    Gomez-Roca, C. A.
    Abdeddaim, C.
    Neuzillet, C.
    Jeannot, E.
    Rocco, E. Guerini
    Frige, G.
    Mazzarella, L.
    Dupain, C.
    Kamal, M.
    Legrand, F.
    Jimenez, M.
    Filleron, T.
    Le Tourneau, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S415 - S415
  • [28] Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma of the penis: Subgroup analysis of the PEVOsq basket trial
    Coquan, E.
    Gomez-Roca, C. A.
    Lambert, A.
    You, B.
    Vansteene, D.
    Bigot, F.
    Cousin, S.
    Castel Ajgal, Z.
    Jeannot, E.
    Rocco, E. Guerini
    Frige, G.
    Mazzarella, L.
    Francisco, M.
    Servant, N.
    Halladjian, M.
    Kamal, M.
    Legrand, F.
    Jimenez, M.
    Cabarrou, B.
    Le Tourneau, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1223 - S1223
  • [29] Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
    Le Saux, O.
    Borel, C.
    Ghiringhelli, F.
    Bigot, F.
    Vansteene, D.
    Chaltiel, R.
    Cousin, S.
    Durando, X.
    Coquan, E.
    Abdeddaim, C.
    Jeannot, E.
    Rocco, E. Guerini
    Frige, G.
    Francisco, M.
    Halladjian, M.
    Kamal, M.
    Legrand, F.
    Jimenez, M.
    Cabarrou, B.
    Le Tourneau, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S515 - S516
  • [30] A phase II trial of reirradiation combined with pembrolizumab in patients with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck (HNSCC)
    Zandberg, Dan Paul
    Bauman, Jessica R.
    Mehra, Ranee
    Molitoris, Jason K.
    Jelinek, Mark
    Wang, Hong
    Clump, David Anthony, II
    Skinner, Heath Devin
    Ferris, Robert L.
    Fenton, Moon Jung
    Cullen, Kevin J.
    Suntharalingam, Mohan
    Bentzen, Soren
    Giri, Anshu
    Liu, Jeffrey C.
    Galloway, Thomas James
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345